Analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the basic materials company’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.
Check Out Our Latest Analysis on Arcadia Biosciences
Arcadia Biosciences Stock Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same quarter in the previous year, the business earned ($2.64) EPS. As a group, equities analysts forecast that Arcadia Biosciences will post -1.7 EPS for the current fiscal year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Articles
- Five stocks we like better than Arcadia Biosciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 9/16 – 9/20
- Profitably Trade Stocks at 52-Week Highs
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.